Acrivon Enterprise Value Over E B I T D A from 2010 to 2024
| ACRV Stock | 6.55 0.11 1.71% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.29) | Current Value (1.36) | Quarterly Volatility 27.03846853 |
Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 22.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.94. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.
Acrivon | Enterprise Value Over E B I T D A |
Latest Acrivon Therapeutics,'s Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Acrivon Therapeutics, Common over the last few years. It is Acrivon Therapeutics,'s Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Acrivon Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (49.66) | |
| Coefficient Of Variation | (54.45) | |
| Mean Deviation | 22.93 | |
| Median | (65.29) | |
| Standard Deviation | 27.04 | |
| Sample Variance | 731.08 | |
| Range | 63.9997 | |
| R-Value | 0.78 | |
| Mean Square Error | 311.88 | |
| R-Squared | 0.60 | |
| Significance | 0.0007 | |
| Slope | 4.70 | |
| Total Sum of Squares | 10,235 |
Acrivon Enterprise Value Over E B I T D A History
About Acrivon Therapeutics, Financial Statements
Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (1.29) | (1.36) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.